Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments

BACKGROUND AND PURPOSE Opiates remain the most effective compounds for alleviating severe pain across a wide range of conditions. However, their use is associated with significant side effects. Neuropeptide FF (NPFF) receptors have been implicated in several opiate‐induced neuroadaptive changes including the development of tolerance. In this study, we investigated the consequences of NPFF receptor blockade on acute and chronic stimulation of opioid receptors in mice by using RF9, a potent and selective antagonist of NPFF receptors that can be administered systemically.

[1]  T. Tzschentke,et al.  Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. , 2010, Drug and alcohol dependence.

[2]  L. Moulédous,et al.  Opioid‐modulating properties of the neuropeptide FF system , 2010, BioFactors.

[3]  C. Parenti,et al.  Selective inhibition of the NOP receptor in the ventrolateral periaqueductal gray attenuates the development and the expression of tolerance to morphine-induced antinociception in rats , 2010, Peptides.

[4]  H. Pan,et al.  Opioid-Induced Long-Term Potentiation in the Spinal Cord Is a Presynaptic Event , 2010, The Journal of Neuroscience.

[5]  J. Sandkühler,et al.  Induction of Synaptic Long-Term Potentiation After Opioid Withdrawal , 2009, Science.

[6]  R. Maldonado,et al.  Nicotine anxiogenic and rewarding effects are decreased in mice lacking β-endorphin , 2009, Neuropharmacology.

[7]  H. Ueda,et al.  Mechanisms underlying morphine analgesic tolerance and dependence. , 2009, Frontiers in bioscience.

[8]  M. Max,et al.  The molecular epidemiology of pain: a new discipline for drug discovery , 2008, Nature Reviews Drug Discovery.

[9]  Rui Wang,et al.  Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice , 2008, Peptides.

[10]  J. Silberring,et al.  Neuropeptide FF (NPFF) reduces the expression of cocaine-induced conditioned place preference and cocaine-induced sensitization in animals , 2008, Peptides.

[11]  J. Silberring,et al.  Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats , 2007, Peptides.

[12]  J. Bourguignon,et al.  Neuropeptide FF and neuropeptide VF inhibit GABAergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleus. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  F. Simonin.  Neuropeptide FF receptors as therapeutic targets , 2006 .

[14]  C. Mollereau,et al.  Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model , 2006, Peptides.

[15]  J. Lassalle,et al.  A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice , 2006, Peptides.

[16]  C. Mollereau,et al.  Opioid-modulating peptides: mechanisms of action. , 2005, Current topics in medicinal chemistry.

[17]  C. Mollereau,et al.  Neuropeptide FF (NPFF) Analogs Functionally Antagonize Opioid Activities in NPFF2 Receptor-Transfected SH-SY5Y Neuroblastoma Cells , 2005, Molecular Pharmacology.

[18]  H. Ueda.  Locus‐Specific Involvement of Anti‐Opioid Systems in Morphine Tolerance and Dependence , 2004, Annals of the New York Academy of Sciences.

[19]  A. Puget,et al.  Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig, and marmoset monkey brains: A comparative autoradiographic study , 2004, Synapse.

[20]  R. Maldonado,et al.  Prevention of fentanyl-induced delayed pronociceptive effects in mice lacking the protein kinase Cγ gene , 2004, Neuropharmacology.

[21]  G. Wilson,et al.  Morphine hyperalgesia: A case report , 2003, The American journal of hospice & palliative care.

[22]  J. Zajac,et al.  Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones , 2003, Neuroscience Letters.

[23]  C. Austin,et al.  Neuropeptide FF receptor 2 (NPFF2) is localized to pain-processing regions in the primate spinal cord and the lower level of the medulla oblongata , 2003, Journal of Chemical Neuroanatomy.

[24]  C. Rivat,et al.  Opioid-induced hyperalgesia: abnormal or normal pain? , 2003 .

[25]  B. Kieffer,et al.  Opioid Tolerance–In Search of the Holy Grail , 2002, Cell.

[26]  D. Sessler,et al.  Acute Opioid Tolerance: Intraoperative Remifentanil Increases Postoperative Pain and Morphine Requirement , 2000, Anesthesiology.

[27]  S. Salvadori,et al.  Characterization of [Nphe1]nociceptin(1‐13)NH2, a new selective nociceptin receptor antagonist , 2000, British journal of pharmacology.

[28]  C. Rivat,et al.  Long-lasting Hyperalgesia Induced by Fentanyl in Rats: Preventive Effect of Ketamine , 2000, Anesthesiology.

[29]  G. McNally.  Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance , 1999, Neuroscience & Biobehavioral Reviews.

[30]  Jianren Mao,et al.  NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity , 1999, Brain Research Reviews.

[31]  J. Zajac,et al.  Neuropeptide FF selectively attenuates the effects of nociceptin on acutely dissociated neurons of the rat dorsal raphe nucleus , 1999, Brain Research.

[32]  E. Huang,et al.  Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs , 1999, Peptides.

[33]  B. Francés,et al.  Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. , 1998, European journal of pharmacology.

[34]  B. Roques,et al.  Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal , 1998, The EMBO journal.

[35]  G. Guilbaud,et al.  Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. , 1997, The Journal of pharmacology and experimental therapeutics.

[36]  E. Borrelli,et al.  Absence of opiate rewarding effects in mice lacking dopamine D2 receptors , 1997, Nature.

[37]  J. Zajac,et al.  Neuropeptide FF reverses the effect of μ‐opioid on Ca2+ channels in rat spinal ganglion neurones , 1996, Neuroreport.

[38]  P. Stevens,et al.  Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome. , 1995, Drug and alcohol dependence.

[39]  D. Price,et al.  Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions , 1995, Pain.

[40]  L. Stinus,et al.  Neuropeptide FLFQPQRFamide receptors within the ventral mesenchephalon and dopaminergic terminal areas: Localization and functional antiopioid involvement , 1995, Neuroscience.

[41]  J. Lake,et al.  Analog of neuropeptide FF attenuates morphine tolerance , 1992, Neuroscience Letters.

[42]  R. Rothman.  A review of the role of anti‐opioid peptides in morphine tolerance and dependence , 1992, Synapse.

[43]  J. Lake,et al.  IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat , 1991, Neuroscience Letters.

[44]  J. L. Sims,et al.  FMRF-NH2-like mammalian octapeptide: Possible role in opiate dependence and abstinence , 1990, Peptides.

[45]  S. Iversen,et al.  The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. , 1990, European journal of pharmacology.

[46]  W. Fratta,et al.  Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Lo,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957 .

[48]  Justin,et al.  RF 9 , a potent and selective neuropeptide FF receptor antagonist , prevents opioid-induced tolerance associated with hyperalgesia , 2006 .

[49]  L. O. Randall,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957, Archives internationales de pharmacodynamie et de therapie.